Post-Marketing Surveillance for the Safety and Effectiveness of Adefovir in Patients with Chronic Hepatitis B |
Shin, Keun-Young
(Department of Internal Medicine, Liver Research Institute Kyungpook National University College of Medicine)
Choi, Hong-Mi (GlaxoSmithKlineKorea) Oh, Shin-Young (GlaxoSmithKlineKorea) Kim, Joon-Hyung (GlaxoSmithKlineKorea) Lee, Yil-Seob (GlaxoSmithKlineKorea) Kweon, Young-Oh (Department of Internal Medicine, Liver Research Institute Kyungpook National University College of Medicine) |
1 | Izzedine H, Hulot JS, Launay-Vacher V, Marcellini P, Hadziyannis SJ, Currie G, Brosgart CL, Westland C, Arterbrun S, Deray G; Adefovir Dipivoxil International 437 Study Group; Adefovir Dipivoxil International 438 Study Group. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B:two double-blind, randomized, placebo-controlled studies. Kidney Int, 2004;66:1153-1158. DOI ScienceOn |
2 | Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 2008;48(3):750-758. DOI ScienceOn |
3 | Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology, 2006;131(6):1743-1751. DOI ScienceOn |
4 | Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology, 2000;119(1):172-180. DOI ScienceOn |
5 | Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis, 2002;2(7):395-403. DOI ScienceOn |
6 | Lee WM. Hepatitis B virus infection. N Engl J Med, 1997;337:1733-1745. DOI ScienceOn |
7 | Lok AS. Navigating the maze of hepatitis B treatments. Gastroenterology, 2007;132(4):1586-1594. DOI ScienceOn |
8 | Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med, 1999;341:1256-1263. DOI ScienceOn |
9 | Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 2003;125(6):1714-1722. DOI ScienceOn |
10 | Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, Manns M, Isom H, Furman P, Locarnini S. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother, 2001;45(9):2495-2501. DOI ScienceOn |
11 | Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, Hardy D, Beall G, Cooper R, Murphy R, Basgoz N, Ng E, Deeks S, Winslow D, Toole JJ, Coakley D. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA, 1999;282(24):2305-2312. DOI ScienceOn |
12 | Lee KS and Kim DJ. Management of Chronic Hepatitis B. Korean J Hepatol, 2007;13(4):447-488. (Korean) DOI ScienceOn |
13 | Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology, 2007;133(5):1445-1451. DOI ScienceOn |
14 | Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, Brosgart C, Fry J, Namini H, Katlama C, Poynard T. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet, 2001;358(9283):718-723. DOI ScienceOn |
15 | Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL; Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 2003;348:808-816. DOI ScienceOn |
16 | Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL; Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med, 2003;348:800-807. DOI ScienceOn |